MENU
IBB
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

IBB stock forecast, quote, news & analysis

The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U... Show more

Category: #Health
IBB
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for IBB with price predictions
Sep 18, 2026

IBB's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Oscillator for IBB moved out of overbought territory on August 27, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 instances where the indicator moved out of the overbought zone. In 29 of the 33 cases the stock moved lower in the days that followed. This puts the odds of a move down at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBB as a result. In 77 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

The Moving Average Convergence Divergence Histogram (MACD) for IBB turned negative on August 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 44 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBB advanced for three days, in 274 of 321 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

IBB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 228 of 243 cases where IBB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Intra-Cellular Therapies (NASDAQ:ITCI).

Industry description

The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Market Cap

The average market capitalization across the iShares Biotechnology ETF (IBB) ETF is 8.23B. The market cap for tickers in the group ranges from 14.86M to 203.47B. AMGN holds the highest valuation in this group at 203.47B. The lowest valued company is APLT at 14.86M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Biotechnology ETF (IBB) ETF was 1%. For the same ETF, the average monthly price growth was -6%, and the average quarterly price growth was 27%. TEM experienced the highest price growth at 32%, while XENE experienced the biggest fall at -32%.

Volume

The average weekly volume growth across all stocks in the iShares Biotechnology ETF (IBB) ETF was 195%. For the same stocks of the ETF, the average monthly volume growth was 49% and the average quarterly volume growth was -24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 70
Price Growth Rating: 47
SMR Rating: 87
Profit Risk Rating: 84
Seasonality Score: -12 (-100 ... +100)
View a ticker or compare two or three
IBB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
415-670-2000
Web
www.ishares.com
IBB's RSI Oscillator peaks and leaves overbought zone